HD-OPM Archive
Topics › Statins

PLANET trial: atorvastatin preferred over rosuvastatin in chronic kidney disease

Louis Nervegna · Jul 13, 2026 · ♥ 5 reactions · 3 comments · original Facebook post
StatinsKidney health
↻ This is a repost. The main version (highest ranked) is PLANET trial: atorvastatin preferred over rosuvastatin in CKD (with July 2026 correction) · Dec 06, 2025.
AI summary & key facts

Louis shares a note on PLANET supporting atorvastatin in CKD, correcting the typo: atorvastatin improved proteinuria but had no effect on eGFR.

Atorvastatin is the preferred statin in patients with chronic kidney disease, per the PLANET trial.

(Note that the post below has a typo. The correct statement is that atorvastatin improved proteinuria, but had no effect on eGFR.)

#ckdHD #atorvastatinHD #rosuvastatinHD #kidneysHD #statinskidneysHD

Research cited

✅✅ATORVASTATIN IS THE PREFERRED STATIN IN CKD PATIENTS

The most common cause of mortality in patients with CKD is cardiovascular, and therefore statins are recommended.

The PLANET (Prospective Evaluation of Proteinuria and Renal Function in Diabetic [and Nondiabetic] Patients With Progressive Renal Disease) trial showed that rosuvastatin was associated with decreased glomerular filtration rate (GFR) and increased proteinuria, whereas atorvastatin improved GFR and had no effect on proteinuria.

← newer: Rosuvastatin can stress kidneys at high dose; atorvastatin aolder: Atorvastatin improved kidney function dose-dependently in 6 →